v3.26.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
12 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Income Statement [Abstract]    
Revenue, Product and Service [Extensible Enumeration] Service [Member] Service [Member]
Oncology revenue $ 59,425 $ 56,944
Costs and operating expenses:    
Cost, Product and Service [Extensible Enumeration] Service [Member] Service [Member]
Cost of oncology revenue $ 30,900 $ 28,389
Research and development 9,084 6,825
Sales and marketing 9,318 7,545
General and administrative 11,152 9,339
Loss on disposal of equipment 111 293
Total costs and operating expenses 60,565 52,391
Income (loss) from operations (1,140) 4,553
Other income:    
Other income, net 211 73
Income (loss) before income tax expense (929) 4,626
Provision (benefit) for income tax 246 (75)
Net income (loss) $ (1,175) $ 4,701
Net income (loss) per common share outstanding    
basic (in dollars per share) $ (0.08) $ 0.34
diluted (in dollars per share) $ (0.08) $ 0.33
Weighted average common shares outstanding    
basic (in shares) 13,832,385 13,659,786
diluted (in shares) 13,832,385 14,266,781